secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K
Filed at:   2026-09-23T00:18:52+00:00
Accession:  0001213900-26-102321
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds completes 1-for-10 reverse stock split; share count falls to 1.51M
--------------------------------------------------------------------------

- Reverse stock split effective 12:01 a.m. ET on July 24, 2026; every 10 shares combined into 1 share.
- Shares outstanding reduced from 15,091,180 to 1,509,118; 33,506 additional shares issued for fractional rounding.
- Par value reduced from $0.01 to $0.001 per share; authorized shares unchanged at 100M common, 10M preferred.
- Common stock trades on NYSE American under 'APUS' on split-adjusted basis; new CUSIP 03771D201.
- Proportionate adjustments made to outstanding equity awards and warrants and their exercise prices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026102321/0001213900-26-102321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026102321/ea0306326-8k_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-102321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer